Combination Encorafenib Plus Binimetinib in Patients With Melanoma

Video

Paolo A. Ascierto, MD, discusses how results from the COLUMBUS trial affect the treatment landscape for patients with BRAF-mutant melanoma.

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses how results from the COLUMBUS trial affect the treatment landscape for patients withBRAF-mutant melanoma.

Ascierto recommends choosing the combination encorafenib (Braftovi) plus binimetinib (Mektovi). While the efficacy appeared similar to other treatments, encorafenib may be considered the “best” BRAF inhibitor.

Related Videos
Related Content
Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment

April 11th 2024
Article

Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.

Read More

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

February 15th 2022
Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Listen

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL

April 10th 2024
Article

In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.

Read More

Targeting Multiple Myeloma With the Latest Therapies

Targeting Multiple Myeloma With the Latest Therapies

April 9th 2024
Article

In an interview with Targeted Oncology, Adam D. Cohen, MD, discussed the impressive efficacy of FDA-approved agents, alongside their toxicity profiles, for the treatment of multiple myeloma.

Read More